HealthCare Global Enterprises Announces Key Corporate Actions

HealthCare Global Enterprises is set to issue 74,21,455 stock options under its new ESOS 2026 scheme.

Reader Takeaway: Revenue growth is positive, but fluctuating PAT and remuneration concerns need attention.

What just happened

HealthCare Global Enterprises (HCG) has announced several key corporate actions through a postal ballot. These include the approval of the 'HCG Employee Stock Option Scheme – 2026' (ESOS 2026), which will create a pool of up to 74,21,455 shares. Additionally, the company has approved a grant of stock options to employees, including one for CEO Dr. Manish Mattoo exceeding 1% of the issued capital (1.24% of diluted equity).

Other significant approvals include the reappointment of Mr. Rajiv Maliwal as Independent Director for a second five-year term and a revision in the remuneration of CEO Dr. Manish Mattoo, effective from April 1, 2026.

Why this matters

These decisions are crucial for aligning employee interests with company performance, incentivizing leadership, and ensuring continued governance. The ESOP scheme aims to reward employees and foster long-term growth. The CEO's revised remuneration and director reappointment provide stability and clear incentives for future performance.

The backstory

HCG is recognized as a leading cancer care network in India. The company has demonstrated consistent year-on-year revenue growth. However, its Profit After Tax (PAT) has seen fluctuations, influenced by operational costs and potentially other factors.

What changes now

With the approval of ESOS 2026, HCG can now grant stock options to its employees, including senior management. The revised remuneration for the CEO and the reappointment of the Independent Director will be effective from their respective dates, pending shareholder approval through the postal ballot.

Risks to watch

• Gestation Costs: New center expansions may incur significant upfront costs, potentially impacting short-term profitability.
• Profit Inadequacy: Past profit levels have been noted as potentially inadequate for statutory remuneration limits, suggesting a need for sustained profit improvement.

Peer comparison

As a leading cancer care network, HCG operates in a competitive healthcare landscape. While specific peer financial data is not provided in the filing, consistent revenue growth is a positive indicator in the sector.

Context metrics (time-bound)

• Total Income: Increased from ₹1,186.86 crore (FY 2023-24) to ₹1,394.97 crore (FY 2025-26).
• EBITDA: Grew from ₹216.79 crore (FY 2023-24) to ₹271.26 crore (FY 2025-26).
• Profit After Tax (PAT): Fluctuated, recorded at ₹32.80 crore (FY 2023-24), ₹3.53 crore (FY 2024-25), and ₹14.58 crore (FY 2025-26).
• ESOS 2026 Pool: 74,21,455 options.
• CEO Dr. Manish Mattoo's proposed Remuneration (from April 1, 2026): Base pay ₹2.75 crore, Variable pay ₹1.25 crore.
• Independent Director Mr. Rajiv Maliwal's proposed Remuneration: ₹35 lakh per annum.
• CEO's ESOP Grant: 18,55,364 options (1.24% of diluted equity).
• Postal Ballot Results Due: By July 10, 2026.

What to track next

Investors should monitor the results of the postal ballot, the effective implementation of the ESOS 2026, and the company's ability to improve its bottom-line profitability while managing the costs associated with expanding its network of oncology centers.